Evoke Pharma's inhaled gastro drug better than oral generic

[riky]

Evoke Pharma's inhaled gastro drug better than oral generic

(Reuters) - Evoke Pharma Inc said its inhaled version of a generic gastrointestinal drug was found to be superior in managing symptoms of bowel disease compared with the existing oral treatment, sending its shares up 45 percent. The results of the mid-stage study, published in a medical journal, tested an intranasal formulation of generic metoclopramide in 89 diabetic gastroparesis patients dosed four times a day for 6 weeks. (The story corrects headline, paragraphs 1 and 2 to say Evoke's drug is an inhaled version of an existing oral generic drug, not a new version of the company's drug.) (Reporting by Natalie Grover in Bangalore;

Source: You are not allowed to view links. Register or Login